{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:45:40Z","timestamp":1761975940983,"version":"3.41.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Hypertrophic cardiomyopathy is a genetic disease that frequently presents at a young age. Pregnancy represents a state of high physiological stress to the cardiovascular system. Thus, pregnant women with hypertrophic cardiomyopathy face the potential for higher morbidity and, therefore, their management may become a significant challenge when complications develop. Physiologic changes that occur during pregnancy, that is, decreased vascular resistance, increased blood volume, and increased heart rate can lead to worsening heart failure in women with hypertrophic cardiomyopathy. In addition, pregnant women with hypertrophic cardiomyopathy are at higher risk for arrhythmias. The hemodynamic effects of atrial fibrillation and ventricular tachycardia are significant and can be dangerous for the mother and the fetus. In addition, they can lead to heart failure exacerbation. Atrial fibrillation is of particular interest in this population subgroup. Pregnancy is a hypercoagulable state and atrial fibrillation is an arrhythmia associated with significant thromboembolic complications. Patients with hypertrophic cardiomyopathy that develop atrial fibrillation are especially at a higher risk of thrombosis. Anticoagulation is recommended regardless of CHA2DS2-VASc score. Anticoagulation during pregnancy is challenging not only because of the teratogenic effects of some drugs and the lack of evidence for some others, but also the differences in the plasma concentration of many anticoagulants. Overall, the potential for high morbidity in pregnant women with hypertrophic cardiomyopathy is not negligible. Major cardiac events such as arrhythmias and heart failure are common. However, early recognition and treatment of these complications can lead to full-term pregnancy and successful delivery.<\/jats:p>","DOI":"10.1097\/crd.0000000000000394","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T02:00:19Z","timestamp":1632535219000},"page":"258-262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The Challenge of Pregnancy in Women With Hypertrophic Cardiomyopathy"],"prefix":"10.1097","volume":"30","author":[{"given":"Amanda","family":"Lloji","sequence":"first","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio A.","family":"Panza","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/0002-9149(79)90160-7","article-title":"Hypertrophic cardiomyopathy: a discussion of nomenclature.","volume":"43","author":"Maron","year":"1979","journal-title":"Am J Cardiol"},{"key":"R2-20250619","first-page":"3461","article-title":"Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes.","volume":"38","author":"Walsh","year":"2017","journal-title":"Eur Heart J"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/HJH.0000000000000090","article-title":"A longitudinal study of maternal cardiovascular function from preconception to the postpartum period.","volume":"32","author":"Mahendru","year":"2014","journal-title":"J Hypertens"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-0-387-74672-2_6","article-title":"The vascular actions of relaxin.","volume":"612","author":"Jeyabalan","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1532-429X-16-1","article-title":"Cardiovascular magnetic resonance in pregnancy: insights from the cardiac hemodynamic imaging and remodeling in pregnancy (CHIRP) study.","volume":"16","author":"Ducas","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/cvr\/cvt208","article-title":"Calcineurin activity is required for cardiac remodelling in pregnancy.","volume":"100","author":"Chung","year":"2013","journal-title":"Cardiovasc Res"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0735-1097(02)02495-6","article-title":"Risk associated with pregnancy in hypertrophic cardiomyopathy.","volume":"40","author":"Autore","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/ehx189","article-title":"Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC).","volume":"38","author":"Goland","year":"2017","journal-title":"Eur Heart J"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CRD.0000000000000010","article-title":"Pregnancy in women with hypertrophic cardiomyopathy.","volume":"22","author":"Schinkel","year":"2014","journal-title":"Cardiol Rev"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0026-895X(25)13904-7","article-title":"Regulation of myometrial adrenoreceptors and adrenergic response by sex steroids.","volume":"20","author":"Roberts","year":"1981","journal-title":"Mol Pharmacol"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"e003182","DOI":"10.1161\/JAHA.115.003182","article-title":"Atrial fibrillation and atrial flutter in pregnant women-A population-based study.","volume":"5","author":"Lee","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.amjcard.2005.11.041","article-title":"Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes.","volume":"97","author":"Silversides","year":"2006","journal-title":"Am J Cardiol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jacep.2015.04.013","article-title":"Atrial fibrillation or flutter during pregnancy in patients with structural heart disease: data from the ROPAC (Registry on Pregnancy and Cardiac Disease).","volume":"1","author":"Salam","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/clc.20326","article-title":"Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service.","volume":"31","author":"Li","year":"2008","journal-title":"Clin Cardiol"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/heart.89.7.752","article-title":"Pregnancy related complications in women with hypertrophic cardiomyopathy.","volume":"89","author":"Thaman","year":"2003","journal-title":"Heart"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacc.2003.08.013","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with supraventricular arrhythmias\u2013executive summary. A report of the American college of cardiology\/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society.","volume":"42","author":"Blomstr\u00f6m-Lundqvist","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R17-20250619","first-page":"558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy.","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.hrthm.2010.07.011","article-title":"Catheter ablation of atrial fibrillation without the use of fluoroscopy.","volume":"7","author":"Reddy","year":"2010","journal-title":"Heart Rhythm"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/pdp.22.4.277.283","article-title":"Warfarin embryopathy.","volume":"22","author":"Chan","year":"2003","journal-title":"Pediatr Pathol Mol Med"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0735-1097(99)00044-3","article-title":"Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves.","volume":"33","author":"Vitale","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIR.0000000000000029","article-title":"2014 AHA\/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Nishimura","year":"2014","journal-title":"Circulation"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.115.015242","article-title":"Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC).","volume":"132","author":"van Hagen","year":"2015","journal-title":"Circulation"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00392-015-0893-5","article-title":"Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.","volume":"105","author":"Hoeltzenbein","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/0002-9149(92)90939-V","article-title":"Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation.","volume":"69","author":"Spirito","year":"1992","journal-title":"Am J Cardiol"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000354953","article-title":"Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy.","volume":"126","author":"Tian","year":"2013","journal-title":"Cardiology"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jce.12982","article-title":"High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device.","volume":"27","author":"Wilke","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2016.08.092","article-title":"Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy.","volume":"119","author":"van Velzen","year":"2017","journal-title":"Am J Cardiol"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","article-title":"Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.","volume":"39","author":"Maron","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.jacc.2016.04.026","article-title":"Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation.","volume":"67","author":"Noseworthy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/europace\/euq013","article-title":"Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression.","volume":"12","author":"Di Donna","year":"2010","journal-title":"Europace"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"e004005","DOI":"10.1161\/CIRCHEARTFAILURE.117.004005","article-title":"Heart failure in pregnant women: a concern across the pregnancy continuum.","volume":"11","author":"Mogos","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2018.02.076","article-title":"Pregnancy outcomes in women with heart disease: the CARPREG II study.","volume":"71","author":"Silversides","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1590\/S0066-782X2007000400019","article-title":"Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy.","volume":"88","author":"Avila","year":"2007","journal-title":"Arq Bras Cardiol"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/hc3001.093437","article-title":"Prospective multicenter study of pregnancy outcomes in women with heart disease.","volume":"104","author":"Siu","year":"2001","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:01:01Z","timestamp":1750356061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000394","relation":{},"ISSN":["1061-5377"],"issn-type":[{"type":"print","value":"1061-5377"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}